Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
NCT05648500 is registered in ClinicalTrials.gov with Viatris Innovation GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
- Lead sponsor
- Viatris Innovation GmbH
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 13, 2022
- Completion date
- September 30, 2027
- Enrollment
- 470 (actual)
- Sites
- 198
Conditions
As the registry lists them; a condition with its own page is linked.